Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer’s Disease Pathogenesis
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Pharmacological interventions in Alzheimer's disease (AD) are likely to be more efficacious if administered early in the course of the disease, foregoing the spread of irreversible changes in the brain. Research findings underline an early vulnerability of the isodendritic core (IC) network to AD neurofibrillary lesions. The IC constitutes a phylogenetically conserved subcortical system including the locus coeruleus in pons, dorsal raphe nucleus, and substantia nigra in the midbrain, and nucleus basalis of Meynert in basal forebrain. Through their ascending projections to the cortex, the IC neurons regulate homeostasis and behavior by synthesizing aminergic and cholinergic neurotransmitters. Here we reviewed the evidence demonstrating that neurons of the IC system show neurofibrillary tangles in the earliest stages of AD, prior to cortical pathology, and how this involvement may explain pre-amnestic symptoms, including depression, agitation, and sleep disturbances in AD patients. In fact, clinical and animal studies show a significant reduction of AD cognitive and behavioral symptoms following replenishment of neurotransmitters associated with the IC network. Therefore, the IC network represents a unique candidate for viable therapeutic intervention and should become a high priority for research in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“In fact, for decades, the amyloid cascade hypothesis dominated the AD field [7].”
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 3×
“In the same line, the neuropathologic diagnosis for AD is based on a combination of Aβ plaques and NFTs [6].”
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529 · cited 1×
“Upon binding to adrenergic receptors, NE regulates critical behavioral and physiologic processes including wakefulness and attention, in both humans and animals [29,54,56].”
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 4×
“Neuropathologically, the LC consistently shows NFTs, even in the absence of Aβ deposition in the brain and as early as 10 years prior to the expected onset of cognitive changes [12,69,70].”
InfluentialMesulam, M. ‐., Mufson, E. J., Levey, A. I., & Wainer, B. H. (1983) · Journal of Comparative Neurology · doi:10.1002/cne.902140206 · Cited by 1,962
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Braak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 1×
“Recently, in an attempt to acknowledge these cases, a neuropathological consensus coined the term primary age related tauopathy (PART) [13,14].”
Self-citationThe Human Central Nervous System
Nieuwenhuys, R., Voogd, J., & van Huijzen, C. (2008) · doi:10.1007/978-3-540-34686-9 · Cited by 1,262
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118
Orienting and reorienting: the locus coeruleus mediates cognition through arousal
Sara, S. J., & Bouret, S. (2012) · Neuron · doi:10.1016/j.neuron.2012.09.011 · Cited by 1,056
Classification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874
A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat
Vertes, R. P. (1991) · Journal of Comparative Neurology · doi:10.1002/cne.903130409 · Cited by 842
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812 · cited 1×
“Braak & Del Tredici, 2011 [42] Examine the AD pathogenesis based on intraneuronal tau lesions in 42 individuals under the age of 30 42 cases (ages of 4– 29): 14 nondemented females and 28 nondemented males (age range 4–29 years).”
Prion-like transmission of protein aggregates in neurodegenerative diseases
Brundin, P., Melki, R., & Kopito, R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2873 · Cited by 778
The human raphe nuclei and the serotonergic system
Hornung, J.-P. (2003) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2003.10.002 · Cited by 742
Modes and models of forebrain cholinergic neuromodulation of cognition
Hasselmo, M. E., & Sarter, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.104 · Cited by 733
Berg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain
Selden, N. (1998) · Brain · doi:10.1093/brain/121.12.2249 · Cited by 657
The neuropathology of aminergic nuclei in Alzheimer's disease
Zweig, R. M., Ross, C. A., Hedreen, J. C., Steele, C., Cardillo, J. E., Whitehouse, P. J., Folstein, M. F., & Price, D. L. (1988) · Annals of Neurology · doi:10.1002/ana.410240210 · Cited by 446
The isodendritic core of the brain stem
Ramón‐Moliner, E., & Nauta, W. J. H. (1966) · Journal of Comparative Neurology · doi:10.1002/cne.901260301 · Cited by 442
Braak, H., & Braak, E. (1996) · Acta Neuropathologica · doi:10.1007/s004010050508 · Cited by 406 · cited 1×
“Their poor or incomplete myelination, as well as being key sources of diffuse (volume) autonomic neurotransmission could expose these nuclei to triggers of AD pathology [27,48,49].”
Grudzien, A., Shaw, P., Weintraub, S., Bigio, E., Mash, D. C., & Mesulam, M. M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.007 · Cited by 396 · cited 2×
“, 2007 [62] Determine whether the LC displays NFTs early in the course of AD.”
Role of norepinephrine in the pathophysiology and treatment of mood disorders
Ressler, K. J., & Nemeroff, C. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00127-4 · Cited by 307
Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology
Schönheit, B., Zarski, R., & Ohm, T. G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.009 · Cited by 262
Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis
Lyness, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00057-x · Cited by 240 · cited 3×
“Although the IC is involved in AD from its earliest stage, probably years before the onset of disease-defining clinical symptoms, such lesions are unlikely benign and may explain behavioral, mood and sleep disturbances seen in AD prodromal stages and along the disease progression, although this need to be confirmed by…”
Neuropsychological Contributions to the Early Identification of Alzheimer’s Disease
Bondi, M. W., Jak, A. J., Delano-Wood, L., Jacobson, M. W., Delis, D. C., & Salmon, D. P. (2008) · Neuropsychology Review · doi:10.1007/s11065-008-9054-1 · Cited by 216
Does Alzheimer's disease begin in the brainstem?
Simic, G., Stanic, G., Mladinov, M., Jovanov‐Milosevic, N., Kostovic, I., & Hof, P. R. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01038.x · Cited by 204 · cited 1×
“These discrepancies may be related to methodological problems such as selection biases, the lack of an integrative approach for studying neuronal loss and protein accumulation in the same brain, as well as the use of unbiased stereology [18,20,45,46].”
MICHELSEN, K., PRICKAERTS, J., & STEINBUSCH, H. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00912-6 · Cited by 196 · cited 1×
“The DRN can be divided into four sub-groups: the supratrochlear, interfascicular, caudal compact and lamellar subnuclei [89,90].”
Kril, J., Patel, S., Harding, A., & Halliday, G. (2002) · Acta Neuropathologica · doi:10.1007/s00401-001-0477-5 · Cited by 190
Mann, D. M. A., Yates, P. O., & Marcyniuk, B. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90439-2 · Cited by 127
The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome
Gibb, W. R., Mountjoy, C. Q., Mann, D. M., & Lees, A. J. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.2.193 · Cited by 122 · cited 4×
“Neuropathological studies confirmed SN susceptibility to NFTs and neurodegeneration in AD, but severe cell loss is rarely present in this nucleus in contrast to the rest of the IC [16,124,125,127,130].”
InfluentialHendricksen, M., Thomas, A. J., Ferrier, I. N., Ince, P., & O’Brien, J. T. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1096 · Cited by 121
Role of Serotonin in Alzheimerʼs Disease: A New Therapeutic Target?
Geldenhuys, W. J., & Van der Schyf, C. J. (2011) · CNS Drugs · doi:10.2165/11590190-000000000-00000 · Cited by 117
Relationship between plaques, tangles, and loss of cortical cholinergic fibers in alzheimer disease
Geula, C., Mesulam, M. M., Saroff, D. M., & Wu, C.-K. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199801000-00008 · Cited by 102
Is Antidepressant Treatment Associated with Reduced Cognitive Decline in Alzheimer’s Disease?
Mossello, E., Boncinelli, M., Caleri, V., Cavallini, M. C., Palermo, E., Di Bari, M., Tilli, S., Sarcone, E., Simoni, D., Biagini, C. A., et al. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000121334 · Cited by 61
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
Cited by
Theofilas, P., Ehrenberg, A. J., Dunlop, S., Di Lorenzo Alho, A. T., Nguy, A., Leite, R. E. P., Rodriguez, R. D., Mejia, M. B., Suemoto, C. K., Ferretti-Rebustini, R. E. D. L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2362 · Cited by 416
Self-citationA clinicopathological approach to the diagnosis of dementia
Elahi, F. M., & Miller, B. L. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.96 · Cited by 412
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
Physiological changes in neurodegeneration—mechanistic insights and clinical utility
Ahmed, R. M., Ke, Y. D., Vucic, S., Ittner, L. M., Seeley, W., Hodges, J. R., Piguet, O., Halliday, G., & Kiernan, M. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.23 · Cited by 91
In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer’s disease
Serra, L., D'Amelio, M., Di Domenico, C., Dipasquale, O., Marra, C., Mercuri, N. B., Caltagirone, C., Cercignani, M., & Bozzali, M. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.012 · Cited by 91
“, 1982) of AD has been extensively investigated, showing that cholinergic dysfunctions in the basal forebrain account formemory deficits in typical AD (Theofilas et al., 2015).”
BackgroundInfluential
Metadata
- Authors
- Theofilas, P., Dunlop, S., Heinsen, H., & Grinberg, L. T.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-05-07
- Volume
- 46
- Issue
- 1
- Pages
- 17-34
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1766764214
- Cited by
- 114
- References
- 43
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.